Long-Term Resident Spaceflight-Associated Neuro-Ocular Syndrome
Earth designation: Long-Term Resident Intracranial Hypertension
Long-Term Resident presentation of Intracranial Hypertension in lunar residents. Elevated intracranial pressure (ICP) associated with fluid redistribution in low gravity. In Earth gravity, blood and CSF are distributed by the hydrostatic pressure gradient. In reduced gravity, cephalad fluid shift occurs — more fluid accumulates in the head, potentially raising intracranial press...
Lunar Risk Factors
Duration of lunar residence (longer = higher cumulative risk). Pre-existing venous anatomy variations. High-intensity exercise promoting cephalad fluid shift. Certain medications. Possible genetic susceptibility.
Symptoms
Headache (especially on waking), visual disturbances, papilledema, pulsatile tinnitus, vision loss.
Lunar Presentation
Often subtle — residents may not report symptoms that they attribute to normal lunar adjustment. Regular ophthalmology screening (portable fundoscopy) detects papilledema before vision loss. Visual field changes are insidious.
Diagnosis
Fundoscopy for papilledema. OCT (optical coherence tomography) for RNFL thickness. MRI for pituitary flattening, optic nerve sheath distension. Lumbar puncture for opening pressure if MRI not available.
Treatment
Acetazolamide, topiramate, CSF diversion (not typically available in lunar medical bay), positional modification.
Lunar Medical Bay Protocol
Acetazolamide (500 mg BID) as first-line ICP reduction. Sleep in 10-15° head elevation. Reduce dietary sodium. Treat any contributing factors. Ophthalmology follow-up every 3 months for affected residents. If visual field loss: urgent Earth telemedicine neurology/ophthalmology. Possible evacuation for advanced cases.
Evacuation Criteria
Progressive visual field loss. Visual acuity decline. Papilledema grade 4+. Opening pressure >30 cmH2O with symptoms. Neurological deterioration.
Prevention
Annual fundoscopy for all residents. OCT monitoring for high-risk residents. Exercise protocols that minimize cephalad fluid shift. Early reporting of visual symptoms.